2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.17E.01 Cost-Effectiveness Analysis of Sotorasib vs. Adagrasib in KRAS G12c-Mutated Previously Treated NSCLC

EP.17E.01 Cost-Effectiveness Analysis of Sotorasib vs. Adagrasib in KRAS G12c-Mutated Previously Treated NSCLC

Pdf Summary

The document presents a cost-effectiveness analysis comparing two FDA-approved KRAS G12C inhibitors, sotorasib and adagrasib, used in previously treated advanced or metastatic non-small-cell lung cancer (NSCLC) with KRAS G12C mutations. Although both drugs display similar efficacy (objective response rate and progression-free survival), sotorasib is identified as being more cost-effective compared to adagrasib. This is primarily attributed to sotorasib’s lower associated costs in adverse event (AE) management, medication use, and dosage interruptions, making it the dominant choice in the cost-effectiveness analysis. <br /><br />The analysis utilizes data from respective phase 2 studies, employing a partition survival model with a lifetime horizon and several key attributes like overall survival (OS) and progression-free survival (PFS) based on parametric curves. Sotorasib demonstrated higher health gains at lower costs, with a cost-effectiveness threshold set at $150,000 per quality-adjusted life-year (QALY), showing a net monetary benefit of $89,892 compared to adagrasib.<br /><br />Additional sensitivity analyses support sotorasib's cost-effectiveness across various scenarios and parameters, reinforcing its advantage in terms of efficacy, acquisition costs, and AE management. The analysis remains consistent despite assumptions and model limitations, such as unavailable clinical inputs for adagrasib and the absence of phase 3 KRYSTAL-12 data, which could potentially affect results.<br /><br />The study concludes that regardless of the variables considered, sotorasib consistently outperforms adagrasib economically, making it the preferable treatment for KRAS G12C-mutated NSCLC patients, attributed to better safety and lower costs of treatment management.

Asset Subtitle

Nadia Karim

Meta Tag

Speaker Nadia Karim

Topic Global Health, Health Services, and Health Economics

Keywords

cost-effectiveness analysis

KRAS G12C inhibitors

sotorasib

adagrasib

non-small-cell lung cancer

NSCLC

progression-free survival

quality-adjusted life-year

adverse event management

economic evaluation